Privia Health Group (PRVA) Financials

Privia Health Group logo
$25.20 -0.06 (-0.22%)
As of 02:14 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Privia Health Group

Annual Income Statements for Privia Health Group

This table shows Privia Health Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
8.24 31 -188 -8.59 23 14 23
Consolidated Net Income / (Loss)
7.95 31 -191 -12 21 17 30
Net Income / (Loss) Continuing Operations
7.95 31 -191 -12 21 17 30
Total Pre-Tax Income
9.15 23 -219 -19 29 28 44
Total Operating Income
16 25 -217 -19 21 17 34
Total Gross Profit
691 712 791 1,186 1,460 1,509 1,870
Total Revenue
786 817 966 1,357 1,658 1,736 2,123
Operating Revenue
786 817 966 1,357 1,658 1,736 2,123
Total Cost of Revenue
95 105 175 171 198 227 253
Operating Cost of Revenue
95 105 175 171 198 227 253
Total Operating Expenses
675 687 1,009 1,205 1,439 1,492 1,836
Selling, General & Admin Expense
42 44 256 130 110 126 138
Marketing Expense
9.16 11 23 20 25 26 27
Depreciation Expense
1.43 1.84 2.46 4.57 6.53 7.27 9.91
Other Operating Expenses / (Income)
623 629 728 1,051 1,299 1,333 1,661
Total Other Income / (Expense), net
-6.91 -1.92 -1.07 0.54 8.37 11 9.70
Other Income / (Expense), net
- - - 0.54 8.37 11 9.70
Income Tax Expense
1.21 -7.44 -28 -6.52 7.99 11 14
Net Income / (Loss) Attributable to Noncontrolling Interest
-0.30 -0.34 -2.42 -3.48 -2.05 2.66 6.81
Basic Earnings per Share
$0.09 $0.33 ($1.83) ($0.08) $0.20 $0.12 $0.19
Weighted Average Basic Shares Outstanding
95.93M 95.95M 102.95M 110.70M 116.73M 119.40M 122.18M
Diluted Earnings per Share
$0.09 $0.33 ($1.83) ($0.08) $0.19 $0.11 $0.18
Weighted Average Diluted Shares Outstanding
95.93M 95.95M 102.95M 110.70M 124.69M 125.61M 128.89M
Weighted Average Basic & Diluted Shares Outstanding
- - 108.17M 115.00M 118.57M 120.51M 123.69M

Quarterly Income Statements for Privia Health Group

This table shows Privia Health Group's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
2.98 3.47 3.54 4.40 4.22 2.69 6.86 9.15 3.06 9.05 13
Consolidated Net Income / (Loss)
3.06 4.64 3.98 5.37 6.05 3.29 9.81 11 3.71 9.73 15
Net Income / (Loss) Continuing Operations
3.06 4.64 3.98 5.37 6.05 3.29 9.81 11 3.71 9.73 15
Total Pre-Tax Income
3.81 8.06 7.98 8.02 8.15 5.74 17 13 9.31 17 22
Total Operating Income
0.82 5.10 5.81 5.25 5.22 3.34 14 11 7.42 12 21
Total Gross Profit
361 365 382 401 421 456 519 474 535 563 587
Total Revenue
415 422 438 461 480 521 580 541 604 633 657
Operating Revenue
415 422 438 461 480 521 580 541 604 633 657
Total Cost of Revenue
54 57 56 60 60 65 61 67 68 69 70
Operating Cost of Revenue
54 57 56 60 60 65 61 67 68 69 70
Total Operating Expenses
360 360 376 396 415 453 505 463 528 552 567
Selling, General & Admin Expense
32 29 31 34 32 38 40 29 41 40 34
Marketing Expense
6.09 6.85 7.05 6.46 6.92 6.81 6.96 6.45 8.13 8.00 9.94
Depreciation Expense
1.82 1.82 1.80 1.83 1.90 2.58 2.77 2.66 3.28 3.36 3.50
Other Operating Expenses / (Income)
320 323 337 353 375 406 455 425 475 500 519
Total Other Income / (Expense), net
2.98 2.97 2.16 2.77 2.93 2.41 2.27 2.09 1.89 4.98 1.72
Interest & Investment Income
- - - - - 2.41 2.27 - - 1.67 1.72
Other Income / (Expense), net
2.98 2.97 2.16 - 2.93 0.00 0.00 2.09 1.89 3.31 0.00
Income Tax Expense
0.75 3.42 4.00 2.66 2.10 2.46 6.87 2.79 5.60 7.02 7.67
Net Income / (Loss) Attributable to Noncontrolling Interest
0.07 1.18 0.44 0.97 1.83 0.60 2.95 1.43 0.65 0.69 1.11
Basic Earnings per Share
$0.03 $0.03 $0.03 $0.03 $0.03 $0.02 $0.06 $0.08 $0.02 $0.07 $0.11
Weighted Average Basic Shares Outstanding
118.51M 119.30M 119.66M 119.40M 120.62M 122.13M 122.77M 122.18M 124.15M 126.12M 127.54M
Diluted Earnings per Share
$0.02 $0.03 $0.03 $0.03 $0.03 $0.02 $0.05 $0.08 $0.02 $0.07 $0.10
Weighted Average Diluted Shares Outstanding
125.05M 125.32M 125.75M 125.61M 127.75M 128.45M 128.78M 128.89M 130.88M 131.83M 132.71M
Weighted Average Basic & Diluted Shares Outstanding
119.32M 119.56M 120.00M 120.51M 121.92M 122.73M 123.00M 123.69M 126.01M 127.73M 127.77M

Annual Cash Flow Statements for Privia Health Group

This table details how cash moves in and out of Privia Health Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
7.78 38 236 27 42 102 -11
Net Cash From Operating Activities
24 39 55 47 81 109 163
Net Cash From Continuing Operating Activities
24 39 55 47 81 109 163
Net Income / (Loss) Continuing Operations
7.95 31 -191 -12 21 17 30
Consolidated Net Income / (Loss)
7.95 31 -191 -12 21 17 30
Depreciation Expense
0.78 1.19 1.15 1.22 1.17 1.10 0.74
Amortization Expense
0.98 0.78 1.47 4.04 5.36 6.16 9.17
Non-Cash Adjustments To Reconcile Net Income
0.21 0.48 267 67 37 57 71
Changes in Operating Assets and Liabilities, net
14 5.54 -24 -13 16 28 53
Net Cash From Investing Activities
-5.71 -0.38 -33 -0.10 -43 -12 -182
Net Cash From Continuing Investing Activities
-5.71 -0.38 -33 -0.10 -43 -12 -182
Acquisitions
0.00 0.00 -32 0.00 -43 -6.96 -180
Other Investing Activities, net
- - - -0.10 -0.11 -5.02 -1.20
Net Cash From Financing Activities
-11 -0.77 214 -20 3.71 4.33 6.70
Net Cash From Continuing Financing Activities
-11 -0.77 214 -20 3.71 4.33 6.70
Payment of Dividends
- - 0.00 0.00 -5.69 0.00 -1.35
Issuance of Common Equity
0.00 0.00 224 0.13 0.66 1.65 0.00
Other Financing Activities, net
0.00 0.11 3.83 13 8.74 2.68 8.05
Cash Interest Paid
9.20 1.93 0.89 0.71 0.04 0.29 0.25
Cash Income Taxes Paid
0.32 0.38 0.50 0.31 1.04 3.76 6.64

Quarterly Cash Flow Statements for Privia Health Group

This table details how cash moves in and out of Privia Health Group's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-38 36 35 69 -22 -79 51 38 -60 -7.32 34
Net Cash From Operating Activities
-33 34 33 75 -24 7.97 52 128 -49 1.10 29
Net Cash From Continuing Operating Activities
-33 34 33 75 -24 7.97 52 128 -49 1.10 29
Net Income / (Loss) Continuing Operations
3.06 4.64 3.98 5.37 6.05 3.29 9.81 11 3.71 9.73 15
Consolidated Net Income / (Loss)
3.06 4.64 3.98 5.37 6.05 3.29 9.81 11 3.71 9.73 15
Depreciation Expense
0.29 0.29 0.29 0.23 0.23 0.19 0.17 0.16 0.15 0.15 0.14
Amortization Expense
1.53 1.53 1.51 1.60 1.67 2.40 2.60 2.50 3.14 3.21 3.36
Non-Cash Adjustments To Reconcile Net Income
11 14 15 15 18 19 19 15 22 18 15
Changes in Operating Assets and Liabilities, net
-49 14 12 52 -50 -17 20 99 -78 -30 -4.22
Net Cash From Investing Activities
-5.71 - - -6.27 0.00 -89 -1.20 -91 -0.03 -11 -1.07
Net Cash From Continuing Investing Activities
-5.71 - - -6.27 0.00 -89 -1.20 -91 -0.03 -11 -1.07
Other Investing Activities, net
-5.01 - - -0.02 0.00 - -1.20 - -0.03 -0.03 -1.07
Net Cash From Financing Activities
0.48 1.75 1.49 0.62 2.24 1.88 0.43 2.15 -11 3.04 6.22
Net Cash From Continuing Financing Activities
0.48 1.75 1.49 0.62 2.24 1.88 0.43 2.15 -11 3.04 6.22
Issuance of Common Equity
- - 0.65 - - - - - - - 0.35
Other Financing Activities, net
0.48 0.75 0.84 0.62 2.24 1.88 0.43 3.49 0.77 0.83 5.87
Cash Interest Paid
0.09 0.06 0.07 0.06 0.00 0.12 0.06 0.06 0.06 0.10 0.13
Cash Income Taxes Paid
-0.23 3.11 0.64 0.23 -0.31 6.08 - 0.87 0.06 11 3.48

Annual Balance Sheets for Privia Health Group

This table presents Privia Health Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
329 686 793 1,000 1,136 1,369
Total Current Assets
190 447 552 701 835 911
Cash & Equivalents
85 321 348 390 491 480
Accounts Receivable
99 117 190 291 316 401
Prepaid Expenses
6.33 8.70 14 21 27 30
Plant, Property, & Equipment, net
4.81 4.50 3.39 2.33 1.24 0.50
Total Noncurrent Assets
134 235 237 297 300 458
Goodwill
119 128 127 139 142 210
Intangible Assets
5.98 60 57 108 110 216
Noncurrent Deferred & Refundable Income Taxes
4.95 33 40 35 26 2.27
Other Noncurrent Operating Assets
4.48 14 13 15 22 30
Total Liabilities & Shareholders' Equity
329 686 793 1,000 1,136 1,369
Total Liabilities
185 236 274 393 452 578
Total Current Liabilities
147 190 264 387 449 569
Accounts Payable
39 46 53 58 82 97
Other Current Liabilities
107 144 211 329 367 472
Total Noncurrent Liabilities
38 46 9.49 5.56 3.19 9.92
Noncurrent Deferred & Payable Income Tax Liabilities
- - - - - 0.00
Other Noncurrent Operating Liabilities
5.60 14 9.49 5.56 3.19 9.92
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
144 450 519 607 683 791
Total Preferred & Common Equity
147 427 499 561 635 737
Total Common Equity
147 427 499 561 635 737
Common Stock
167 635 716 755 814 894
Retained Earnings
-20 -208 -217 -194 -179 -156
Noncontrolling Interest
-3.10 23 20 46 48 54

Quarterly Balance Sheets for Privia Health Group

This table presents Privia Health Group's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
938 992 1,032 1,078 1,146 1,184 1,273 1,351 1,418 1,489 1,564
Total Current Assets
654 698 728 780 854 886 883 971 966 1,025 1,100
Cash & Equivalents
318 330 351 387 422 469 390 441 420 412 446
Accounts Receivable
320 350 346 370 409 389 444 499 514 574 624
Prepaid Expenses
16 17 31 22 23 28 49 31 33 39 30
Plant, Property, & Equipment, net
2.88 2.60 2.04 1.75 1.46 1.01 0.83 0.66 0.38 0.27 1.02
Total Noncurrent Assets
281 292 301 296 290 296 389 379 451 463 463
Goodwill
135 136 139 139 139 142 172 172 210 216 216
Intangible Assets
96 107 106 105 103 108 170 168 213 219 215
Noncurrent Deferred & Refundable Income Taxes
37 35 34 31 28 25 24 17 0.00 0.00 0.00
Other Noncurrent Operating Assets
12 14 22 21 20 22 23 23 29 29 32
Total Liabilities & Shareholders' Equity
938 992 1,032 1,078 1,146 1,184 1,273 1,351 1,418 1,489 1,564
Total Liabilities
366 401 409 434 483 474 539 588 612 651 691
Total Current Liabilities
358 394 404 430 479 471 535 583 601 634 674
Accounts Payable
49 54 51 61 66 68 74 85 81 91 100
Other Current Liabilities
310 340 353 369 414 403 461 498 521 543 575
Total Noncurrent Liabilities
7.82 7.08 4.96 4.42 3.91 3.20 4.14 5.31 11 16 16
Noncurrent Deferred & Payable Income Tax Liabilities
- - - - - - - - 0.25 3.74 3.94
Other Noncurrent Operating Liabilities
7.82 7.08 4.96 4.42 3.91 3.20 4.14 5.31 10 12 13
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
571 591 623 644 662 710 734 763 806 838 873
Total Preferred & Common Equity
525 545 577 595 615 659 683 709 753 782 816
Total Common Equity
525 545 577 595 615 659 683 709 753 782 816
Common Stock
727 741 767 783 799 834 855 875 906 927 946
Retained Earnings
-202 -196 -191 -187 -184 -175 -172 -165 -153 -144 -131
Noncontrolling Interest
46 46 46 48 47 50 51 54 53 56 57

Annual Metrics And Ratios for Privia Health Group

This table displays calculated financial ratios and metrics derived from Privia Health Group's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - -
Revenue Growth
0.00% 3.91% 18.25% 40.41% 22.19% 4.74% 22.26%
EBITDA Growth
0.00% 53.44% -885.60% 93.80% 366.88% -1.17% 53.24%
EBIT Growth
0.00% 58.01% -956.72% 91.46% 256.19% -3.97% 57.65%
NOPAT Growth
0.00% 139.74% -555.31% 91.21% 211.78% -30.59% 123.02%
Net Income Growth
0.00% 288.97% -716.91% 93.67% 274.30% -18.95% 74.41%
EPS Growth
0.00% 266.67% -654.55% 95.63% 337.50% -42.11% 63.64%
Operating Cash Flow Growth
0.00% 59.66% 41.57% -14.28% 71.17% 35.28% 49.53%
Free Cash Flow Firm Growth
0.00% 0.00% -274.17% 89.95% -43.02% 212.89% -366.36%
Invested Capital Growth
0.00% 0.00% 74.98% 5.48% 27.37% -11.74% 61.86%
Revenue Q/Q Growth
0.00% 0.00% 6.81% 7.03% 4.83% 1.17% 3.93%
EBITDA Q/Q Growth
0.00% 0.00% -11.90% 62.42% 29.88% 72.57% 12.95%
EBIT Q/Q Growth
0.00% 0.00% -12.12% 54.37% 35.12% 111.87% 13.86%
NOPAT Q/Q Growth
0.00% 0.00% -12.12% 53.04% -44.83% 35.99% 29.30%
Net Income Q/Q Growth
0.00% 0.00% -8.95% 70.43% -40.85% 21.73% 21.29%
EPS Q/Q Growth
0.00% 0.00% -9.58% 78.38% -44.12% 10.00% 38.46%
Operating Cash Flow Q/Q Growth
0.00% 0.00% -14.02% 724.82% 76.24% 10.85% 47.61%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 82.50% 46.34% 27.91% -51.31%
Invested Capital Q/Q Growth
0.00% 0.00% 115.01% -1.79% -16.41% -19.94% -3.16%
Profitability Metrics
- - - - - - -
Gross Margin
87.89% 87.15% 81.92% 87.41% 88.08% 86.93% 88.09%
EBITDA Margin
2.27% 3.35% -22.23% -0.98% 2.14% 2.02% 2.54%
Operating Margin
2.04% 3.11% -22.50% -1.41% 1.25% 0.98% 1.61%
EBIT Margin
2.04% 3.11% -22.50% -1.37% 1.75% 1.61% 2.07%
Profit (Net Income) Margin
1.01% 3.78% -19.73% -0.89% 1.27% 0.98% 1.40%
Tax Burden Percent
86.81% 131.71% 87.25% 64.93% 72.46% 61.16% 67.65%
Interest Burden Percent
56.98% 92.45% 100.49% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
13.19% -31.71% 0.00% 0.00% 27.54% 38.84% 32.35%
Return on Invested Capital (ROIC)
0.00% 72.14% -119.45% -8.03% 7.69% 5.06% 9.20%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 82.05% -96.77% -8.45% 6.05% 3.55% 7.85%
Return on Net Nonoperating Assets (RNNOA)
0.00% -29.11% 55.24% 5.54% -3.96% -2.42% -5.17%
Return on Equity (ROE)
0.00% 43.03% -64.21% -2.49% 3.73% 2.64% 4.03%
Cash Return on Invested Capital (CROIC)
0.00% -127.86% -173.98% -13.37% -16.38% 17.54% -38.05%
Operating Return on Assets (OROA)
0.00% 7.72% -42.83% -2.51% 3.24% 2.61% 3.51%
Return on Assets (ROA)
0.00% 9.39% -37.55% -1.63% 2.35% 1.60% 2.37%
Return on Common Equity (ROCE)
0.00% 43.95% -62.02% -2.38% 3.52% 2.45% 3.75%
Return on Equity Simple (ROE_SIMPLE)
0.00% 21.06% -44.66% -2.42% 3.75% 2.68% 0.00%
Net Operating Profit after Tax (NOPAT)
14 33 -152 -13 15 10 23
NOPAT Margin
1.77% 4.09% -15.75% -0.99% 0.90% 0.60% 1.09%
Net Nonoperating Expense Percent (NNEP)
0.00% -9.91% -22.68% 0.42% 1.65% 1.51% 1.35%
Return On Investment Capital (ROIC_SIMPLE)
- - - -2.58% 2.46% 1.52% 2.93%
Cost of Revenue to Revenue
12.11% 12.85% 18.08% 12.59% 11.92% 13.07% 11.91%
SG&A Expenses to Revenue
5.32% 5.39% 26.48% 9.55% 6.61% 7.27% 6.51%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
85.84% 84.04% 104.42% 88.82% 86.83% 85.95% 86.48%
Earnings before Interest and Taxes (EBIT)
16 25 -217 -19 29 28 44
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
18 27 -215 -13 36 35 54
Valuation Ratios
- - - - - - -
Price to Book Value (P/BV)
0.00 3.06 6.45 5.20 4.84 3.69 3.96
Price to Tangible Book Value (P/TBV)
0.00 20.29 11.52 8.25 8.63 6.11 9.36
Price to Revenue (P/Rev)
0.57 0.55 2.85 1.91 1.64 1.35 1.37
Price to Earnings (P/E)
54.40 14.35 0.00 0.00 117.81 163.09 127.25
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
1.84% 6.97% 0.00% 0.00% 0.85% 0.61% 0.79%
Enterprise Value to Invested Capital (EV/IC)
0.00 4.26 15.36 13.26 10.90 9.90 8.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.48 2.58 1.67 1.43 1.10 1.17
Enterprise Value to EBITDA (EV/EBITDA)
0.00 14.42 0.00 0.00 66.81 54.16 46.25
Enterprise Value to EBIT (EV/EBIT)
0.00 15.54 0.00 0.00 81.85 68.29 56.68
Enterprise Value to NOPAT (EV/NOPAT)
0.00 11.80 0.00 0.00 158.77 183.25 107.52
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 10.14 45.23 48.05 29.40 17.42 15.24
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 52.92 0.00
Leverage & Solvency
- - - - - - -
Debt to Equity
0.00 0.23 0.07 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.23 0.07 0.00 0.00 0.00 0.00
Financial Leverage
0.00 -0.35 -0.57 -0.66 -0.65 -0.68 -0.66
Leverage Ratio
0.00 2.29 1.71 1.53 1.59 1.65 1.70
Compound Leverage Factor
0.00 2.12 1.72 1.53 1.59 1.65 1.70
Debt to Total Capital
0.00% 18.98% 6.75% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.49% 0.18% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 18.49% 6.56% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% -1.75% 4.83% 3.84% 7.57% 7.06% 6.79%
Common Equity to Total Capital
0.00% 82.76% 88.43% 96.16% 92.43% 92.94% 93.21%
Debt to EBITDA
0.00 1.23 -0.15 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 -1.86 1.34 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 1.20 -0.15 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 1.01 -0.21 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 -1.52 1.89 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.98 -0.21 0.00 0.00 0.00 0.00
Altman Z-Score
0.00 4.26 7.38 7.38 6.02 4.91 4.82
Noncontrolling Interest Sharing Ratio
0.00% -2.16% 3.40% 4.46% 5.85% 7.30% 6.92%
Liquidity Ratios
- - - - - - -
Current Ratio
0.00 1.29 2.35 2.09 1.81 1.86 1.60
Quick Ratio
0.00 1.25 2.30 2.03 1.76 1.80 1.55
Cash Flow Metrics
- - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -59 -222 -22 -32 36 -96
Operating Cash Flow to CapEx
426.66% 10,234.47% 10,065.45% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 -30.91 -207.19 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
3.53 20.29 51.46 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
2.70 20.09 50.94 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - -
Asset Turnover
0.00 2.48 1.90 1.83 1.85 1.63 1.69
Accounts Receivable Turnover
0.00 8.24 8.93 8.84 6.90 5.72 5.92
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 169.73 207.43 343.98 580.54 973.59 2,431.66
Accounts Payable Turnover
0.00 2.68 4.10 3.46 3.57 3.25 2.83
Days Sales Outstanding (DSO)
0.00 44.28 40.90 41.30 52.88 63.79 61.65
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 136.44 89.03 105.57 102.18 112.41 129.11
Cash Conversion Cycle (CCC)
0.00 -92.16 -48.13 -64.27 -49.29 -48.62 -67.46
Capital & Investment Metrics
- - - - - - -
Invested Capital
0.00 93 162 171 218 192 311
Invested Capital Turnover
0.00 17.63 7.58 8.14 8.52 8.47 8.43
Increase / (Decrease) in Invested Capital
0.00 93 69 8.89 47 -26 119
Enterprise Value (EV)
0.00 394 2,490 2,268 2,375 1,903 2,490
Market Capitalization
449 449 2,755 2,596 2,719 2,346 2,916
Book Value per Share
$0.00 $1.53 $4.01 $4.37 $4.76 $5.29 $5.99
Tangible Book Value per Share
$0.00 $0.23 $2.25 $2.75 $2.67 $3.20 $2.53
Total Capital
0.00 177 483 519 607 683 791
Total Debt
0.00 34 33 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 33 32 0.00 0.00 0.00 0.00
Net Debt
0.00 -51 -288 -348 -390 -491 -480
Capital Expenditures (CapEx)
5.71 0.38 0.55 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 -41 -63 -60 -76 -105 -137
Debt-free Net Working Capital (DFNWC)
0.00 44 257 288 314 386 342
Net Working Capital (NWC)
0.00 43 256 288 314 386 342
Net Nonoperating Expense (NNE)
6.00 2.52 38 -1.32 -6.07 -6.66 -6.56
Net Nonoperating Obligations (NNO)
0.00 -51 -288 -348 -390 -491 -480
Total Depreciation and Amortization (D&A)
1.76 1.96 2.62 5.26 6.53 7.27 9.91
Debt-free, Cash-free Net Working Capital to Revenue
0.00% -4.97% -6.57% -4.45% -4.56% -6.07% -6.46%
Debt-free Net Working Capital to Revenue
0.00% 5.39% 26.61% 21.21% 18.93% 22.21% 16.13%
Net Working Capital to Revenue
0.00% 5.28% 26.52% 21.21% 18.93% 22.21% 16.13%
Earnings Adjustments
- - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 ($1.83) ($0.08) $0.20 $0.12 $0.19
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 102.95M 110.70M 116.73M 119.40M 122.18M
Adjusted Diluted Earnings per Share
$0.00 $0.00 ($1.83) ($0.08) $0.19 $0.11 $0.18
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 102.95M 110.70M 124.69M 125.61M 128.89M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 108.17M 115.00M 118.57M 120.51M 123.69M
Normalized Net Operating Profit after Tax (NOPAT)
14 18 -152 -13 15 10 23
Normalized NOPAT Margin
1.77% 2.17% -15.75% -0.99% 0.90% 0.60% 1.09%
Pre Tax Income Margin
1.16% 2.87% -22.61% -1.37% 1.75% 1.61% 2.07%
Debt Service Ratios
- - - - - - -
EBIT to Interest Expense
2.32 13.24 -203.21 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
2.02 17.44 -142.25 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
1.50 13.04 -203.72 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
1.19 17.24 -142.76 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 27.08% 0.00% 4.52%
Augmented Payout Ratio
0.00% 0.00% -6.66% 0.00% 27.08% 0.00% 4.52%

Quarterly Metrics And Ratios for Privia Health Group

This table displays calculated financial ratios and metrics derived from Privia Health Group's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - - - - - 123,688,289.00 126,012,374.00 127,734,207.00
DEI Adjusted Shares Outstanding
- - - - - - - - 123,688,289.00 126,012,374.00 127,734,207.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - 0.02 0.07 0.11
Growth Metrics
- - - - - - - - - - -
Revenue Growth
7.50% 2.17% 4.95% 4.55% 15.62% 23.40% 32.54% 17.42% 25.78% 21.39% 13.19%
EBITDA Growth
-67.17% 4.17% -3.81% 121.80% 78.57% -15.74% 98.90% 62.65% 25.28% 211.52% 40.04%
EBIT Growth
-87.74% 3.44% -5.37% 269.58% 114.05% -28.77% 109.03% 66.68% 14.25% 352.13% 42.62%
NOPAT Growth
-86.89% -48.45% -25.71% 354.09% 486.00% -34.94% 192.23% 154.28% -23.60% 258.26% 58.94%
Net Income Growth
-52.26% -27.00% -33.05% 130.94% 97.84% -29.18% 146.53% 97.22% -38.64% 196.05% 48.81%
EPS Growth
-66.67% -50.00% -40.00% 50.00% 50.00% -33.33% 66.67% 166.67% -33.33% 250.00% 100.00%
Operating Cash Flow Growth
-147.59% 353.10% 47.61% 16.69% 27.39% -76.87% 56.83% 70.46% -105.58% -86.20% -44.35%
Free Cash Flow Firm Growth
60.95% 100.06% 128.31% 163.18% 237.42% -192,680.00% -411.18% -478.23% -505.00% 11.31% -26.12%
Invested Capital Growth
10.76% 1.14% -7.86% -11.74% -11.59% 34.01% 33.82% 61.86% 60.86% 24.01% 32.74%
Revenue Q/Q Growth
-5.80% 1.71% 3.69% 5.25% 4.17% 8.55% 11.37% -6.76% 11.58% 4.77% 3.85%
EBITDA Q/Q Growth
-17.17% 273.75% -1.09% -27.56% 41.95% -17.14% 133.46% -17.55% -21.44% 46.45% 30.40%
EBIT Q/Q Growth
-42.04% 879.83% -1.08% -34.21% 55.28% -29.51% 190.29% -19.81% -30.37% 62.01% 36.19%
NOPAT Q/Q Growth
-14.56% 344.30% -1.24% 21.12% 10.26% -50.67% 343.61% 5.39% -66.87% 131.31% 96.80%
Net Income Q/Q Growth
31.50% 51.93% -14.32% 34.92% 12.65% -45.62% 198.27% 7.93% -64.95% 162.37% 49.93%
EPS Q/Q Growth
0.00% 50.00% 0.00% 0.00% 0.00% -33.33% 150.00% 60.00% -75.00% 250.00% 42.86%
Operating Cash Flow Q/Q Growth
-151.70% 204.01% -3.81% 125.61% -132.17% 133.13% 552.29% 145.22% -138.80% 102.22% 2,530.64%
Free Cash Flow Firm Q/Q Growth
44.11% 100.17% 52,712.42% 24.43% 21.56% -341.07% 14.66% -51.24% -30.17% 47.21% -21.35%
Invested Capital Q/Q Growth
24.70% -5.68% -6.27% -19.94% 24.91% 42.98% -6.41% -3.16% 24.14% 10.22% 0.18%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
86.98% 86.48% 87.20% 87.03% 87.60% 87.54% 89.41% 87.65% 88.67% 89.04% 89.40%
EBITDA Margin
0.64% 2.34% 2.23% 1.54% 2.09% 1.60% 3.35% 2.96% 2.09% 2.91% 3.66%
Operating Margin
0.20% 1.21% 1.33% 1.14% 1.09% 0.64% 2.48% 2.08% 1.23% 1.86% 3.13%
EBIT Margin
0.20% 1.91% 1.82% 1.14% 1.70% 1.10% 2.87% 2.47% 1.54% 2.38% 3.13%
Profit (Net Income) Margin
0.74% 1.10% 0.91% 1.16% 1.26% 0.63% 1.69% 1.96% 0.61% 1.54% 2.22%
Tax Burden Percent
80.27% 57.58% 49.87% 66.90% 74.19% 57.24% 58.82% 79.16% 39.85% 58.11% 65.55%
Interest Burden Percent
462.58% 100.00% 100.00% 152.86% 100.00% 100.00% 100.00% 100.00% 100.00% 111.06% 108.39%
Effective Tax Rate
19.73% 42.42% 50.13% 33.10% 25.81% 42.76% 41.18% 20.84% 60.15% 41.89% 34.45%
Return on Invested Capital (ROIC)
1.04% 4.63% 4.54% 6.45% 5.68% 2.32% 10.62% 13.91% 3.51% 6.63% 13.34%
ROIC Less NNEP Spread (ROIC-NNEP)
0.31% 4.14% 4.25% 6.03% 5.15% 1.97% 10.31% 13.57% 3.34% 5.91% 13.09%
Return on Net Nonoperating Assets (RNNOA)
-0.18% -2.40% -2.55% -4.11% -3.17% -1.11% -6.25% -8.93% -1.96% -3.02% -7.10%
Return on Equity (ROE)
0.86% 2.22% 1.99% 2.34% 2.51% 1.21% 4.37% 4.98% 1.55% 3.61% 6.24%
Cash Return on Invested Capital (CROIC)
-6.06% 2.15% 11.23% 17.54% 17.50% -24.98% -22.55% -38.05% -39.60% -14.40% -19.59%
Operating Return on Assets (OROA)
0.35% 3.21% 2.92% 1.85% 2.76% 1.78% 4.70% 4.19% 2.66% 4.07% 5.22%
Return on Assets (ROA)
1.30% 1.85% 1.46% 1.89% 2.05% 1.02% 2.76% 3.31% 1.06% 2.63% 3.71%
Return on Common Equity (ROCE)
0.80% 2.05% 1.84% 2.17% 2.33% 1.12% 4.06% 4.63% 1.45% 3.37% 5.82%
Return on Equity Simple (ROE_SIMPLE)
3.07% 2.68% 2.28% 0.00% 3.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
0.66 2.94 2.90 3.51 3.87 1.91 8.47 8.93 2.96 6.84 13
NOPAT Margin
0.16% 0.70% 0.66% 0.76% 0.81% 0.37% 1.46% 1.65% 0.49% 1.08% 2.05%
Net Nonoperating Expense Percent (NNEP)
0.72% 0.48% 0.29% 0.42% 0.53% 0.35% 0.31% 0.34% 0.17% 0.72% 0.25%
Return On Investment Capital (ROIC_SIMPLE)
- - - 0.51% 0.55% 0.26% 1.11% 1.13% 0.37% 0.82% 1.54%
Cost of Revenue to Revenue
13.02% 13.52% 12.80% 12.97% 12.40% 12.46% 10.59% 12.35% 11.33% 10.96% 10.60%
SG&A Expenses to Revenue
7.74% 6.85% 7.01% 7.47% 6.61% 7.20% 6.83% 5.41% 6.87% 6.27% 5.24%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
86.78% 85.27% 85.87% 85.89% 86.51% 86.90% 86.93% 85.56% 87.44% 87.18% 86.27%
Earnings before Interest and Taxes (EBIT)
0.82 8.06 7.98 5.25 8.15 5.74 17 13 9.31 15 21
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
2.64 9.88 9.77 7.08 10 8.33 19 16 13 18 24
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
4.01 3.48 3.54 3.69 4.10 4.11 4.31 3.96 3.38 4.14 3.08
Price to Tangible Book Value (P/TBV)
6.98 5.90 5.85 6.11 6.60 8.24 8.27 9.36 7.70 9.32 6.54
Price to Revenue (P/Rev)
1.37 1.22 1.27 1.35 1.50 1.48 1.50 1.37 1.13 1.38 1.03
Price to Earnings (P/E)
123.43 138.88 169.78 163.09 173.20 188.95 168.22 127.25 116.91 115.29 72.38
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.81% 0.72% 0.59% 0.61% 0.58% 0.53% 0.59% 0.79% 0.86% 0.87% 1.38%
Enterprise Value to Invested Capital (EV/IC)
7.39 6.77 7.51 9.90 9.52 7.18 8.30 8.00 5.64 6.78 4.98
Enterprise Value to Revenue (EV/Rev)
1.19 1.02 1.05 1.10 1.27 1.30 1.31 1.17 0.97 1.22 0.87
Enterprise Value to EBITDA (EV/EBITDA)
92.22 86.65 88.53 54.16 57.79 64.85 55.97 46.25 38.62 41.88 28.05
Enterprise Value to EBIT (EV/EBIT)
136.05 134.70 137.04 68.29 70.98 82.45 69.15 56.68 48.28 50.77 33.75
Enterprise Value to NOPAT (EV/NOPAT)
186.97 207.30 236.04 183.25 171.96 201.08 148.96 107.52 98.40 106.63 66.57
Enterprise Value to Operating Cash Flow (EV/OCF)
32.90 19.74 18.28 17.42 19.32 26.83 24.10 15.24 15.78 22.01 19.67
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 316.73 64.11 52.92 51.05 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.56 -0.58 -0.60 -0.68 -0.62 -0.56 -0.61 -0.66 -0.59 -0.51 -0.54
Leverage Ratio
1.62 1.66 1.71 1.65 1.66 1.71 1.75 1.70 1.72 1.76 1.78
Compound Leverage Factor
7.48 1.66 1.71 2.53 1.66 1.71 1.75 1.70 1.72 1.95 1.93
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
7.39% 7.49% 7.14% 7.06% 7.06% 6.91% 7.03% 6.79% 6.56% 6.65% 6.55%
Common Equity to Total Capital
92.61% 92.51% 92.86% 92.94% 92.94% 93.09% 92.97% 93.21% 93.44% 93.35% 93.45%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
5.15 4.61 4.39 4.84 5.18 4.77 4.84 4.75 4.26 4.79 3.99
Noncontrolling Interest Sharing Ratio
7.57% 7.76% 7.47% 7.30% 7.21% 7.18% 7.08% 6.92% 6.79% 6.77% 6.78%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.80 1.81 1.78 1.86 1.88 1.65 1.67 1.60 1.61 1.62 1.63
Quick Ratio
1.73 1.76 1.73 1.80 1.82 1.56 1.61 1.55 1.55 1.55 1.59
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-26 0.04 23 29 35 -85 -73 -110 -143 -76 -92
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
1.77 1.68 1.61 1.63 1.63 1.62 1.64 1.69 1.73 1.71 1.67
Accounts Receivable Turnover
5.56 4.92 4.52 5.72 4.90 4.67 4.50 5.92 4.98 4.63 4.34
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
657.20 733.58 846.94 973.59 1,180.37 1,476.36 1,928.77 2,431.66 3,214.01 4,291.30 2,896.62
Accounts Payable Turnover
4.27 3.90 3.66 3.25 3.91 3.56 3.27 2.83 3.52 3.22 2.97
Days Sales Outstanding (DSO)
65.67 74.25 80.71 63.79 74.45 78.19 81.13 61.65 73.31 78.80 84.15
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
85.48 93.59 99.68 112.41 93.25 102.63 111.67 129.11 103.72 113.39 122.70
Cash Conversion Cycle (CCC)
-19.81 -19.34 -18.97 -48.62 -18.80 -24.44 -30.54 -67.46 -30.42 -34.59 -38.55
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
272 256 240 192 240 343 321 311 386 426 427
Invested Capital Turnover
6.53 6.65 6.85 8.47 7.04 6.34 7.27 8.43 7.17 6.13 6.51
Increase / (Decrease) in Invested Capital
26 2.89 -20 -26 -31 87 81 119 146 82 105
Enterprise Value (EV)
2,008 1,735 1,803 1,903 2,286 2,465 2,668 2,490 2,178 2,886 2,126
Market Capitalization
2,313 2,074 2,177 2,346 2,706 2,804 3,056 2,916 2,544 3,242 2,515
Book Value per Share
$4.87 $4.99 $5.14 $5.29 $5.47 $5.60 $5.78 $5.99 $6.09 $6.21 $6.39
Tangible Book Value per Share
$2.80 $2.94 $3.11 $3.20 $3.40 $2.79 $3.01 $2.53 $2.67 $2.76 $3.01
Total Capital
623 644 662 683 710 734 763 791 806 838 873
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-351 -387 -422 -491 -469 -390 -441 -480 -420 -412 -446
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-27 -37 -48 -105 -54 -42 -53 -137 -55 -21 -21
Debt-free Net Working Capital (DFNWC)
324 350 374 386 416 348 388 342 365 391 425
Net Working Capital (NWC)
324 350 374 386 416 348 388 342 365 391 425
Net Nonoperating Expense (NNE)
-2.40 -1.71 -1.08 -1.86 -2.17 -1.38 -1.34 -1.66 -0.75 -2.89 -1.13
Net Nonoperating Obligations (NNO)
-351 -387 -422 -491 -469 -390 -441 -480 -420 -412 -446
Total Depreciation and Amortization (D&A)
1.82 1.82 1.80 1.83 1.90 2.58 2.77 2.66 3.28 3.36 3.50
Debt-free, Cash-free Net Working Capital to Revenue
-1.59% -2.20% -2.78% -6.07% -2.98% -2.21% -2.61% -6.46% -2.44% -0.91% -0.87%
Debt-free Net Working Capital to Revenue
19.23% 20.65% 21.81% 22.21% 23.08% 18.32% 19.00% 16.13% 16.23% 16.57% 17.46%
Net Working Capital to Revenue
19.23% 20.65% 21.81% 22.21% 23.08% 18.32% 19.00% 16.13% 16.23% 16.57% 17.46%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.03 $0.03 $0.03 $0.03 $0.03 $0.02 $0.06 $0.08 $0.02 $0.07 $0.11
Adjusted Weighted Average Basic Shares Outstanding
118.51M 119.30M 119.66M 119.40M 120.62M 122.13M 122.77M 122.18M 124.15M 126.12M 127.54M
Adjusted Diluted Earnings per Share
$0.02 $0.03 $0.03 $0.03 $0.03 $0.02 $0.05 $0.08 $0.02 $0.07 $0.10
Adjusted Weighted Average Diluted Shares Outstanding
125.05M 125.32M 125.75M 125.61M 127.75M 128.45M 128.78M 128.89M 130.88M 131.83M 132.71M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
119.32M 119.56M 120.00M 120.51M 121.92M 122.73M 123.00M 123.69M 126.01M 127.73M 127.77M
Normalized Net Operating Profit after Tax (NOPAT)
0.66 2.94 4.07 3.51 3.87 1.91 8.47 8.93 5.20 6.84 13
Normalized NOPAT Margin
0.16% 0.70% 0.93% 0.76% 0.81% 0.37% 1.46% 1.65% 0.86% 1.08% 2.05%
Pre Tax Income Margin
0.92% 1.91% 1.82% 1.74% 1.70% 1.10% 2.87% 2.47% 1.54% 2.65% 3.39%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.52% 46.69% 37.80% 33.11%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.52% 46.69% 37.80% 33.11%

Financials Breakdown Chart

Key Financial Trends

Privia Health Group’s latest statements show strong top-line growth and improving profitability, although cash generation has become a key concern. The available quarterly data spans Q3 2022 through Q2 2026, with several prior periods marked as restated; comparisons should therefore be interpreted with some caution.

  • Revenue growth remains robust. Q2 2026 revenue reached $632.6 million, up 21.4% from $521.2 million in the restated Q2 2025 period and approximately 84.5% above Q3 2022 revenue of $342.9 million.
  • Gross margins have gradually expanded. Gross profit increased to $563.3 million in Q2 2026, while the gross margin improved to approximately 89.0%, compared with 87.6% in Q2 2025 and 87.2% in Q2 2024.
  • Profitability is improving. Q2 2026 operating income rose to $11.8 million from $7.4 million in Q1 2026 and $3.3 million in Q2 2025. Net income attributable to common shareholders increased to $9.0 million from $2.7 million year over year, while diluted EPS rose to $0.07 from $0.02.
  • The balance sheet remains largely debt-free. The statements show no short-term or long-term debt, and Privia held $412.2 million of cash and equivalents at June 30, 2026. Total equity and noncontrolling interests of $838.1 million exceeded total liabilities of $650.5 million.
  • Retained earnings are moving in the right direction. Retained earnings improved to negative $144.2 million in Q2 2026 from negative $172.3 million in Q2 2025 and negative $234.5 million in Q3 2022, reflecting the company’s cumulative profitability.
  • Recent investing spending has moderated. Q2 2026 investing cash outflow was $11.5 million, a substantial improvement from the $89.1 million outflow in Q2 2025 and the $91.3 million acquisition-related outflow in Q4 2025. However, the data does not show whether the related acquisitions are producing adequate returns.
  • Goodwill and intangible assets are becoming more significant. These assets totaled $434.4 million at the end of Q2 2026, or roughly 29% of total assets, compared with approximately $313.8 million in Q2 2024. This reflects expansion activity but increases exposure to future impairment charges if acquired businesses underperform.
  • Operating cash flow weakened sharply. Privia generated only $1.1 million of operating cash flow in Q2 2026, compared with $8.0 million in Q2 2025 and $52.0 million in Q3 2025. First-half 2026 operating cash flow was negative $48.4 million, versus negative $16.1 million in the comparable 2025 period.
  • Working capital is absorbing cash. Changes in operating assets and liabilities used $30.4 million in Q2 2026 and $78.4 million in Q1 2026. Accounts receivable increased to $574.2 million, up 11.8% from Q1 2026 and 29.3% from Q2 2025, outpacing revenue growth and warranting monitoring of collections.
  • Share dilution and current-liability concentration remain risks. Basic weighted-average shares increased to 126.1 million in Q2 2026 from 122.1 million in Q2 2025. In addition, other current liabilities reached $543.4 million, representing most of the company’s $634.4 million in current liabilities and contributing to a current ratio of approximately 1.6.

Overall, the statements point to a business with accelerating revenue, improving margins and stronger earnings, supported by a sizable cash balance and minimal reported debt. However, the recent deterioration in operating cash flow, rapid growth in receivables and continued share issuance make cash conversion and balance-sheet execution important issues for investors to watch.

11/17/26 02:14 PM ETAI Generated. May Contain Errors.

Privia Health Group Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Privia Health Group's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Privia Health Group's net income appears to be on an upward trend, with a most recent value of $29.73 million in 2025, rising from $7.95 million in 2019. The previous period was $17.04 million in 2024. See where experts think Privia Health Group is headed by visiting Privia Health Group's forecast page.

Privia Health Group's total operating income in 2025 was $34.24 million, based on the following breakdown:
  • Total Gross Profit: $1.87 billion
  • Total Operating Expenses: $1.84 billion

Over the last 6 years, Privia Health Group's total revenue changed from $786.36 million in 2019 to $2.12 billion in 2025, a change of 170.0%.

In the past 13 quarters, Privia Health Group's cash and equivalents has ranged from $317.95 million in Q2 2023 to $469.33 million in Q1 2025, and is currently $446.28 million as of their latest financial filing in Q3 2026.

Privia Health Group had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2019.

Over the last 6 years, Privia Health Group's book value per share changed from 0.00 in 2019 to 5.99 in 2025, a change of 599.4%.



Financial statements for NASDAQ:PRVA last updated on 11/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners